Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad s Life Science Q4 Sales Grew 16.4 Percent, Ex-Currency Benefits; Total Sales Jump 19.3 Percent

NEW YORK, Feb. 17 (GenomeWeb News) - Bio-Rad today reported a 19.3-percent increase in total net sales during then fourth quarter, while sales from its Life Science segment jumped 16.4 percent, excluding currency benefits.

Total net sales for the Hercules, Calif.-based life-sciences company increased to $307.9 million during the fourth quarter of 2004 from $258 million in the year-ago quarter. With currency benefits, net sales in the Life Science segment grew 21.6 percent to $148.5 million, the firm said.

 

Bio-Rad said that the revenue increase in Life Science was helped along by its August 2004 acquisition of MJ GeneWorks.

 

R&D spending during the three months ended Dec. 31, 2004, inched up to $31.9 million from $25.6 million year over year, Bio-Rad said.

 

The company said net income in the quarter fell to $17.1 million, or $.65 per share, from $19.2 million, or $.73 per share.

 

Bio-Rad said it had around $195.7 million in cash and equivalents and $165.9 million in short-term investments as of Dec. 31, 2004.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.